“Autoimmune Diabetes Mellitus Induced by Pembrolizumab: A Case Report and Clinical Implications”

https://pubmed.ncbi.nlm.nih.gov/38116162

This abstract describes a case report of a patient who developed autoimmune diabetes mellitus after treatment with the immune checkpoint inhibitor pembrolizumab, resulting in multiple hospitalizations for diabetic ketoacidosis; the authors emphasize the importance of recognizing this rare complication to enable earlier diagnosis and effective management.